Keratin 17 modulates the immune topography of pancreatic cancer

Lyanne Delgado-Coka,Michael Horowitz,Mariana Torrente-Goncalves,Lucia Roa-Peña,Cindy V. Leiton,Mahmudul Hasan,Sruthi Babu,Danielle Fassler,Jaymie Oentoro,Ji-Dong K Bai,Emanuel F. Petricoin,Lynn M. Matrisian,Edik Matthew Blais,Natalia Marchenko,Felicia D. Allard,Wei Jiang,Brent Larson,Andrew Hendifar,Chao Chen,Shahira Abousamra,Dimitris Samaras,Tahsin Kurc,Joel Saltz,Luisa F. Escobar-Hoyos,Kenneth R. Shroyer

DOI: https://doi.org/10.1186/s12967-024-05252-1

IF: 8.44

2024-05-13

Journal of Translational Medicine

Abstract:The immune microenvironment impacts tumor growth, invasion, metastasis, and patient survival and may provide opportunities for therapeutic intervention in pancreatic ductal adenocarcinoma (PDAC). Although never studied as a potential modulator of the immune response in most cancers, Keratin 17 (K17), a biomarker of the most aggressive (basal) molecular subtype of PDAC, is intimately involved in the histogenesis of the immune response in psoriasis, basal cell carcinoma, and cervical squamous cell carcinoma. Thus, we hypothesized that K17 expression could also impact the immune cell response in PDAC, and that uncovering this relationship could provide insight to guide the development of immunotherapeutic opportunities to extend patient survival.

medicine, research & experimental

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of keratin 17 (K17) in the immune microenvironment of pancreatic ductal adenocarcinoma (PDAC), especially how K17 expression affects the distribution and quantity of immune cells within and around the tumor. Specifically, the researchers hope to reveal the potential mechanism of K17 in the PDAC immune response by analyzing the relationship between K17 expression and immune cells (such as CD8+ T cells, CD16+ macrophages and CD163+ macrophages), thereby providing a theoretical basis for the development of new immunotherapy methods.

### Background
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal type of cancer, not only because it is usually diagnosed at a late stage, but also because it has a natural resistance to conventional chemotherapeutic drugs such as gemcitabine and 5 - fluorouracil, and also has a poor response to immune checkpoint inhibitors. Therefore, understanding the interaction between PDAC and the immune system is crucial for the development of more effective immunotherapy strategies.

### Research Hypothesis
The researchers hypothesized that the expression of K17 might affect the immune cell response in PDAC, especially the quantity and distribution of CD8+ T cells, CD16+ macrophages and CD163+ macrophages within and around the tumor. This hypothesis is based on the known immunomodulatory role of K17 in other cancer types, such as basal cell carcinoma, head and neck cancer and cervical squamous cell carcinoma.

### Methods
The researchers used multiplex immunohistochemistry (mIHC) and an automated image analysis method based on a new computational imaging technique to analyze tumor tissue sections from 235 PDAC patients. Through these methods, the researchers were able to quantify the relationship between K17 expression and different immune cell types and evaluate whether these relationships were affected by neoadjuvant therapy, tumor stage, grade, lymph node status, and KRAS, p53, SMAD4 and CDKN2A mutations.

### Results
The study found that K17 expression significantly affected the exclusion of CD8+ T cells within the tumor and was associated with a decrease in the number of CD8+ T cells, CD16+ macrophages and CD163+ macrophages around the tumor (p < 0.0001). These differences were not affected by neoadjuvant therapy, tumor stage, grade, lymph node status, or the above - mentioned gene mutations.

### Conclusions
The expression of K17 is associated with significant differences in the immune microenvironment, and these differences are independent of any tested clinicopathological or tumor - intrinsic variables. This indicates that targeting K17 - mediated immune effects may restore the innate immune response in PDAC and provide new immunotherapy opportunities for this most lethal form of cancer.

### Formula
The "Tumor/Stromal Zone Score" (\( Z_{\text{Sic}}^M \)) used in the study is defined as follows:
\[ Z_{\text{Sic}}^M=\frac{\text{Cell Count}_{\text{ic}}^M}{\text{Tumor / Stroma Zone}_M} \]
where:
- \( \text{Cell Count}_{\text{ic}}^M \) represents the number of a specific type of immune cell in the K17 - positive or - negative area.
- \( \text{Tumor / Stroma Zone}_M \) represents the total area of the tumor - associated stromal region.

Through this score, the researchers were able to quantify the distribution differences of different immune cells in the K17 - positive and - negative areas.